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Summary 
The CD44-negative T  lymphoma AKR1 (CD44.2 genotype) was transfected  with a CD44.1 
cDNA. The intact eDNA conferred on the transfected cells the ability to bind hyaluronic acid 
(HA) both from solution and immobilized on culture plates. It also conferred a CD44-dependent 
and hyaluronidase-sensitive increase in adhesion to a lymph node endothelial cell line. A mutant 
cDNA which codes for a CD44 molecule lacking most of the cytoplasmic domain of CD44 
was also transfected into AKR1, and cell sorting was used to sdect transfectants expressing levels 
of cell surface CD44 expression comparable with the line transfected with the wild-type CD44 
cDNA. The cells transfected with the mutant construct bound fluoresceinated HA from solution 
very poorly, but did adhere to immobilized HA, though less well than ceils transfected  with 
the wild-type construct. This result indicates that the cytoplasmic domain of CD44 is necessary 
for binding of HA from solution but is not required for binding to immobilized HA, although 
it may contribute to adhesion following ligand recognition. A  monoclonal antibody (mAb), 
IILAWB  14, which reacts with CD44 on all CD44 + cells dramatically induced HA binding 
by some CD44 + cell lines that did not constitutively bind HA. The transfectant expressing a 
CD44 molecule with a truncated cytoplasmic domain could be induced by this antibody to bind 
fluoresceinated-HA  from solution.' Splenic T cells did not bind fluoresceinated HA constitutively. 
In the presence of the IKAWB  14  mAb,  virtually all  CD44 +  splenic  T  cells bound HA. 
Induction was immediate and occurred equally well at room temperature and at 4~  indicating 
that the new HA-binding activity was due to preexistent CD44 molecules.  These results are 
compatible with an antibody-induced activation of CD44 by either a conformational change 
in the CD44 molecule or a change in the distribution of CD44 molecules on the cell surface. 
I 
t has recently been established  that the murine Pgp-1 al- 
loantigen, Ly-24 alloantigen, and hyaluronic acid receptor, 
as well as the human CD44 antigen, Hermes antigens, ECM- 
III receptor, p85, and In (Lu)-related p80 are all identical or 
closely related molecules (1-6). We will refer here to the mol- 
ecules bearing these determinants as CD44. This broadly dis- 
tributed membrane glycoprotein has been implicated in several 
important hematopoietic ceU functions including lymphocyte 
and progenitor cell homing, lymphopoiesis and T eell acti- 
vation (7-14), as well as fibroblast  adhesion and migration 
(15). It now seems likely that the diverse activities attributed 
to CD44 are subsumed by its function as a cell adhesion 
molecule. 
Sequencing of cDNAs of human and mouse CD44 revealed 
a conserved amino terminal region with sequence similarity 
to hyaluronic acid-binding domains of cartilage link and pro- 
teoglycan core proteins (16-21). This suggested a possible func- 
tion in binding hyaluronic acid  (HA). 1 CD44-dependent 
HA  binding  activity  has  been  demonstrated for  several 
CD44 + hematopoietic cell lines (22, 23), for a recombinant 
fusion protein of human CD44 (24),  and for a B cell line 
transfected with the hematopoietic form of human CD44 
(25). CD44 has also been reported to bind extracellular ma- 
trix (ECM) proteins, (collagen types I and VI, and fibronectin) 
(26) and a ligand on high endothdial venules (HEV)-vas- 
cular addressin  (27). 
Ahhough CD44-dependent HA-binding activity can be 
1  Abbreviations used in  this paper: ECM,  e~tracellular  matrix;  H-HA, 
fluorescein-conjugated hyahronic acid; HA, hyahronic acid; HEV, high 
endothelial venules; TME, transformed mouse endothdium; w.t., wild-type~ 
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examples of CD44 + cells that do not bind HA. In partic- 
ular, HA binding activity has not been readily demonstrable 
among the CD44 + normal hematopoietic cells in the mouse 
(22, 23, 28). Thus, CD44 expression  alone does not confer 
HA binding activity (29). 
Molecular cloning and biochemical studies suggest that 
there may be as many as four protein isoforms of CD44. The 
major species on hematopoietic cells, CD44H, has a core trans- 
membrane polypeptide of 37 kD and typically shows an Mr 
of about 90 kD  (19-21).  A  second major form of CD44, 
CD44E, characteristic  of epithelial cells, contains an insert 
(132 aa in the human) in the extraceUular portion of the mol- 
ecule near the transmembrane region (25, 30, 31). Transfec- 
tion of CD44E cDNA into a CD44-negative B cell line did 
not confer hyaluronic acid-dependent binding of the trans- 
fectants to lymph node HEV cultures (25). Both the shorter 
(hematopoietic) and larger (epithelial)  core proteins are ex- 
tensively and diversely modified by glycosylation  (1, 2, 4, 25, 
30, 32), which accounts in part for the many different forms 
found in different cell lines. A minor isoform of CD44H with 
a truncated cytoplasmic tail may exist (33), and there are in- 
dications that CD44 may exist as a soluble protein (34). 
The structural requirements for HA recognition by CD44 
are not well-defined, and it is not known why many CD44 + 
cells do not bind HA. Here, we demonstrate that CD44H 
confers HA binding activity when transfected into a T lym- 
phoma line lacking CD44 expression and that the cytoplasmic 
domain contributes to binding of HA from solution. We also 
describe an antibody to a particular CD44 epitope that dra- 
matically increases the ability of CD44-bearing cells to recog- 
nize HA. We discuss the implications of these results for un- 
derstanding the mechanism of HA binding by CD44. 
Materials  and Methods 
Cells and  mAbs.  The  murine  T  lymphomas  AKK1  (35), 
BW5147 (36), and the CD44  hi variant of SAKKTLS 12 (29) were 
maintained in DMEM with 10% horse serum. AKR1 is negative 
for CD44 expression (7) and for HA binding (22). The LN en- 
dothelial cell line TME-3H3 (37) was maintained on tissue culture 
dishes in DMEM with 10% FCS. 
T cell-enriched spleen cells were prepared from the spleens of 
AICR/Cum mice (Cumberland View Farms, Clinton, TN) by pan- 
ning on petri dishes coated with rabbit anti-rat Ig (38). 
mAbs, used as tissue culture supernatants were: rat anti-mouse 
CD44 IM7 (7), KM201 (11), and IRAWB 14 (this paper); CD44 
allele-specific antibodies (39), RAMB44 specific for CD44.1, and 
C71/26 specific  for CD44.2; and anti-V-CAM-1 antibody M/K-2 
(40, 41). IRAWB 14 mAb was obtained as previously described 
(7) by fusion of $194 myeloma cells with spleen cells of a Sprague- 
Dawley  rat which had been immunized with an HA-binding  variant 
line of SAKRTLS 12 (29) induced with PMA (22, 29) to further 
increase HA binding activity. The hybridoma was chosen on the 
basis of screening for effects  on the binding of fluoresceinated-HA 
to BW5147 cells (see Fig. 3). 
Construction of  Plasraids  for Expression of  CD44.  A cDNA clone 
MHK6 (provided by E. Butcher, Stanford University School of 
Medicine, Stanford, CA) encoding full length murine CD44.1 was 
modified as follows to permit the stable expression of wild-type 
CD44. The entire insert was cut out by EcoRI digestion (20) and 
subcloned into double stranded M13mp18, to yield a single strand 
template. A 25-met oligonucleotide  5' GTC CAT GC~ GAA TTC 
GTG CGG GAT G 3' was used to insert an EcoRI site 3 nucleotide 
residues before  the initiation codon ATG by in vitro oligonucleotide- 
directed mutagenesis.  The mutated insert was digested  with EcoRI 
and subdoned into vector pBG367 (42) yielding  phsmid pMCD44/ 
BG367. A SalI/XhoI fragment from pMCD44/BG367 which con- 
tains 3' termination sequences necessary for expression was sub- 
cloned  into vector pTCFMo  (43), resulting in the expression  plasmid 
for wild-type CD44.1, pMCD44/TCFMo. Expression is driven by 
a long term repeat (LTR) promoter and contains the neo gene to 
allow selection in G418 (Gibeo Laboratories, Grand Island, NY). 
For the construction of a plasmid for expression of CD44.1 with 
a truncated cytoplasmic  domain, the mutated insert was subjected 
to another cycle of in vitro oligonucleotide-directed  mutagenesis 
with the use of a 25-met oligonucleotide 5' TTC TTC TGC CCT 
TTA CAC CTT CTC C Y, which inserted a stop codon TAA at the 
position of Gly278. This insert was subcloned into pBG367 and 
pTCFMo as above, yielding the expression vector pMCD44ACY/ 
TCFMo coding for a CD44.1 molecule containing a deletion of 
all but the first six residues of the cytoplasmic domain. Both in- 
serts were checked by sequencing, and no mutations other than 
the desired ones were found. 
Tmnsfec~ by Electrolxvration.  Cells  were transfected  by electropo- 
ration as described previously (44). Briefly, AKR1 cells were sus- 
pended at  1.0  x  107/ml in ice-cold phosphate-buffered saline 
(Mg  2+  and Ca  2§  free). 0.5 ml of the cell suspension was trans- 
ferred into a precooled  electroporation  cuvette and 80/~g of  purified 
plasmid DNA was added. The cuvette was then pulsed using the 
Gene Pulser apparatus (Bio-Rad  Laboratories,  Richmond, CA) with 
550 V and 25 uF of capacitance. G418 was added at 1 mg/ml after 
48 h of growth and drug-resistant colonies appeared within 2 wk. 
Flow Micnofluorometry  and Cell Sorting.  Fluorescein-conjugated 
HA (F1-HA) was prepared as described (45) using rooster comb 
HA (Sigma Chemical Co., St. Louis, MO). Purified IM7 (7) mAb 
was conjugated with fluorescein  using FITC-celite (22). Labeling 
of cells for flow cytometry, data collection on the Salk Institute's 
modified  Los Alamos flow microfluorometer,  and processing of the 
data were as previously described (46). Geometric mean fluores- 
cence of unstained cells was assigned a value of 1.0 U and positive 
fluorescence was expressed relative to this. Blocking and enhance- 
ment of F1-HA binding was performed by adding hybridoma su- 
pernatant (1:20 final dilution) or unlabeled HA (100/~g/ml final 
concentration) to cells and shaking for 30 s on a micro shaker  just 
before adding the F1-HA. 
To select transfectants expressing CD44 with a deletion of the 
cytoplasmic domain at levels equivalent to the level of CD44 ex- 
pressed by transfectants for the wild-type gene, cells were stained 
with fluorescein-conjugated IM7 mAb and sorted for the most 
fluorescent cells (29). After three cycles  of enrichment sorting, the 
cells were cloned by limit dilution, and clones were screened for 
expression of CD44 comparable to that of AKK1 cells transfected 
with the wild-type CD44 construct. 
Cell Adhesion Assays.  SlCr labeling of lymphoma cells and 
adhesion to HA-coated  plates were performed  as described  by Miyake 
et al. (23). For adhesion to TME-3H3 cells (37), the adherent cells 
were harvested with trypsin, washed and plated at 1-2  x  104 per 
well in 24-well plates (Corning cell wells, #25820; Corning Glass 
Works, Corning, NY) the day before the assay.  Just before addi- 
tion of StCr-labeled lymphoma cells, the adherent TME-3H3 cells 
were rinsed once with warm DMEM with 5% newborn calf serum 
258  Hyaluronic  Acid Binding by CD44 (Hyclone Laboratories, Logan, UT). Incubations and washes were 
the same as for adhesion to HA-coated wells (23). 
For antibody blocking of adhesion, a 1:20 dilution  of culture 
supernatant  containing  mAb was mixed  with  the SlCr-labeled 
lymphoma cells just before their  addition  to the assay plate. 
Northern Blotting, Cell Surface Labeling, and Immunoprecipitation. 
Northern blotting was performed  as described in reference 41. 
Lactoperoxidase-catalyzed iodination, immunotnecipitation  (using 
a rabbit anti-rat  Ig serum) and SDS-polyacrflamide gel electropho- 
resis were as described previously (47). 
Results 
CD44 Expression by Transfectants.  Expression of the trans- 
fected CD44 genes was confirmed by Northern blotting, im- 
munoprecipitation  of surface  *2sI-iodinated  proteins,  and 
flow cytometry. As shown in Fig.  1 A, AKR1 cells trans- 
fected  with  the  wild-type  CD44  cDNA  construct 
(AKR1.CD44 + w.t.) bound high levels of CD44-specific an- 
tibody (fluorescein-conjugated IM7) with over 80% of the 
cells averaging 40 times the background  staining.  A  small 
negative population of variable size was consistently seen and 
could not be eliminated entirely by recloning or culture in 
G418. 
AKR1 cells transfected with  a cDNA construct  coding 
for a CD44 molecule with a truncated cytoplasmic domain 
(see Materials and Methods) originally expressed lower levels 
of CD44 than AKR1.CD44 + w.t. This difference in expres- 
sion made it difficult to compare the HA-binding  activity 
of these two transfected cell lines. We used enrichment sorting 
(see  Materials  and  Methods)  to  isolate  a  derivative, 
AKR.CD44 + ACY, that  expressed CD44 at levels equiva- 
lent to the transfectant for the wild type construct (Fig. 1, G). 
Fig. 2 A  shows Northern blots of the CD44 transcripts 
in the transfected AKR1 cells.  A control B cell line,  BM2 
(23), has three prominent transcripts at 4.6, 3.3, and 1.8 kb. 
Transfected cells have a single transcript of 1.8 kb, which is 
absent  in the parental line. 
Immunoprecipitation  of  lzsI-CD44  from  the  AKR1. 
CD44 + w.t. and AKR1.CD44 + ACY cell lines is shown in 
Fig. 2 B, using mAb specific for the alternative  alleles of CD44 
(39) to confirm that the cells are expressing the transfected, 
and  not  the  endogenous  allele.  The  T  cell  lymphoma, 
BW5147,  expresses the CD44.2  allele  characteristic of the 
AKR/J strain of mouse from which both the BW5147 and 
AKR1 cell lines  were derived (lanes 1 and 2). AKR1 cells 
transfected with  wild-type CD44.1  cDNA,  CD44 §  w.t., 
express CD44.1,  but not CD44.2,  and the labeled protein 
has the same Mr as CD44 from BW5147 (lanes  3  and 4). 
The AKR1 cells transfected with the mutant CD44.1 con- 
struct, CD44 ACY, also express CD44.1, but on a molecule 
that is about 10 kD smaller than the CD44 + w.t. molecule 
(lanes  5  and 6). 
Binding of Fl-HAfrom Solution.  Binding of FI-HA to trans- 
fectants (Fig.  1, B and H) was assayed by flow cytometry as 
described  previously  (22).  Most  AKR1.CD44 +  w.t.  cells 
bound high levels of FI-HA (about 30 x  background). With 
the AKR1.CD44 + ACY transfectant, most cells showed no 
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Figure 1.  CD44  expression and hyaluronic acid binding activity of AKR1 cells transfected with CD44 eDNA constructs. AKR1 cells trans~-cted 
with a w.t. CD44 eDNA construct (A-F) and a mutant cDNA construct that resulted in a truncated cytoplasmic domain (G-L), were stained with 
fluorescein-conjugated  mAb IM7.8.1, specific  for CD44 (A and G), or fluorescein-conjugated  hyaluronic acid (F1-HA) (B-F  and H-L). FI-HA-labeled 
cells were pretreated with KM201 w_Ab  (C and/) or IRAWB 14 mAb (E, F, K, and L) and/or unlabeled hyaluron/c acid (D, F,J, and L) (see Materials 
and Methods). The dotted-line insert in each panel is the fluorescence profile of unstained cells, which was assigned a relative fluorescence  value 
of 1.0 U. 
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of lZSl-surface  labeled  CD44 in AKR.1 cells  transfected  with CD44 cDNA 
constructs. (.4) CD44 mRNA accumulation  by AKR1 cell lines trans- 
fected with CD44 constructs  determined  by Northern blotting. BM2 is 
a CD44+ control cell line (23). Numerals  indicate  apprcc:imate  size of 
transcripts in kb. (B) Cell surface-iodinated  BW5147 (lanes I  and 2), 
AKR1.CD44  + w.t. (lanes  3 and 4) and AKR.1.CD44  + ACY (lane  5 and 
6) cells  were  solubflized  in NP40, and CD44 was immtmoprecipitated  with 
mAb RAMB44 (lanes I, 3, and 5) specific  for CD44.1 or mAb C71/26 
(lanes  2, 4, and 6) specific  for CD44.2. Imrnunoprecipitates  were  electro- 
phoresed on a 7.5% polyacrylamide-SDS  gel 
binding above background but a variable minor population 
bound up to about 10 times above background. In both lines, 
the F1-HA binding detected was inhibited by unlabeled HA 
(Fig. 1, D and.]) and by the CD44-specific antibody KM201 
(Fig.  1, C  and/), which has previously been shown to in- 
hibit binding of cells to HA-coated plastic dishes (see refer- 
ences 23 and Table 1), establishing the specificity and CD44- 
dependence of the HA binding.  The parental line AKR1, 
bound neither CD44-specific antibody nor HA (reference 22 
and data not  shown). 
Binding to Immobilized HA.  Binding of transfected cells 
to HA immobilized on plastic was performed as previously 
described (23). As shown in Table 1, the parental line AKR1 
did not  adhere to  HA-coated plates.  The AKR1.  CD44 + 
w.t.  transfectant bound well to the dishes (40%  as shown 
in  Table  1,  42.0  +  4.6%  in  four  experiments).  The 
AKK1.CD44 + ACY line also bound to HA coated dishes, 
but binding was reduced compared to AKR1.CD44 + w.t., 
although both cell lines express comparable levels of CD44. 
Binding by the transfected cell line expressing CD44 with 
a truncated cytoplasmic domain was consistently observed 
to be about half or less than half the level of binding by the 
cell line transfected with the wild-type CD44 construct. CD44 
levels were analyzed by flow cytometry at the time of each 
adhesion  assay  and  were  always  approximately  the  same 
(40-50x  background) for the two lines. 
Binding to TME-3H3 Cells.  An SV40 transformed, LN- 
derived endothdial cell line TME-3H3  (37) was used as a 
target for cell adhesion assays. As shown in Table 2, AKR1 
parental cells adhered to this cell line and transfection of wild- 
type CD44 into the AKR1  cell line resulted in a twofold 
increase in adhesion to TME-3H3 cells. This increased binding 
was inhibitable by KM201 antibody, indicating that it was 
due to CD44. An antibody specific for a V-CAM-l-like de- 
terminant of stromal cells (41) did not inhibit.  Binding of 
the parental line, AKR1, was not inhibited by either KM201 
or the V-CAM-l-specific antibody. This result suggests that 
the basal binding of the parental AKR1 cell line to 3H3 calls 
is  not  mediated by either CD44  or VLA-4,  the counter- 
receptor of VCAM-1 (40). In other experiments (not shown) 
antibodies against VLA-4, Thy-1, LFA-1, and ICAM-1 failed 
to inhibit  the basal binding of the AKR1 cell line. 
TME-3H3 cells were treated with hyaluronidase to deter- 
mine if the CD44-dependent component of the binding was 
due to recognition of HA (Table 3). Hyaluronidase reduced 
the binding of the CD44  transfected cells and the residual 
binding was not further reduced by KM201. This suggested 
that HA was the ligand mediating the binding activity due 
to CD44  (KM201  inhibitable),  while the residual binding 
(non-CD44) was not directed to  HA. 
The transfectant expressing CD44 with a truncated cyto- 
plasmic domain also bound to 3H3 cells,  though less well 
than  had the transfectant expressing wild-type CD44.  Its 
binding was also reduced by hyaluronidase treatment of the 
endothelial cell monolayer to the same level as that seen when 
binding of this transfectant to untreated TME-3H3 cells was 
assayed in the presence of KM201  antibody (Table  3). 
Antibod  7 Enhancement  of  Hyaluronate  Binding.  In an effort 
to identify cell surface determinants specifically involved in 
the binding of hyaluronic acid, mAbs were made against an 
HA-binding mutant of the AKK/J lymphoma SAKRTLS 
12 induced with PMA to increase HA binding activity (29). 
Antibodies were screened for ability to influence binding of 
F1-HA to BW5147, which already bound HA significantly. 
One of the antibodies, IRAWB 14, markedly increased the 
260  Hyahronic ,A~d Binding  by CD44 Table  1.  Adhesion  to HA Immobilized on Plastic* 
Input  Mean cpmll 
Cell line  Antibody*  cpmS  adhering  Adheringl 
AKR1 parent  -  69,544  1,018  _+  594  1.5%  _+ 0.8 
+KM201  424  _+  10  0.6% 
AKR1.CD44+w.t  -  82,454  33,105  _+  808  40.1%  _+  1.0 
+KM201  337  _+  28  0.4% 
AKR1.CD44+ACY  -  56,722  10,158  _+  709  17.9%  _+  1.2 
+ KM201  203  _+  7  0.4% 
* Adhesion assays performed as described in Materials and Methods and Reference 23. 
Antibody was a 1:20 dilution of hybridoma supernatant, added to the SlCr-labeled cells just  prior to their addition to culture wells. 
S Input cpm listed here  z  input cpm at the start of incubation  -  spontaneous release. 
II Mean and standard error of triplicate samples. 
1% Adhering  ~  cpm adhering/input  cpm (as defined in S). 
binding of F1-HA to BW5147 cells (Fig. 3, compare B and 
E). This antibody also induced H-HA binding by several T 
cell lines which expressed CD44 but did not bind HA, such 
as EL4 and SAKRTLS 12 (22),  and the CD44  hl variant of 
SAKRTLS 12  (29),  which binds F1-HA poorly (Fig.  3, H 
and K).  On the basis of immunoprecipitation  and the pat- 
tern of binding on CD44 + and CD44- cell lines, it was de- 
termined that the IRAWB 14 antibody recognizes a CD44 
Table  2.  CD44-mediated  Adhesion  to  TME-3H3 
Endothelial  Cell Line* 
%  of 
Input cpm 
Cell line  Antibody*  adheringS  Inhibition 
% 
AKR1 parent  -  43.5  _+  1.5  - 
+ KM201 
(anti-CD44)  41.0  +  2.1  6 
+ M/K-2 
(anti-V-CAM-I)  53.6  +  2.4  0 
AKR1.CD44+w.t.  -  89.9  +  1.9  - 
+KM201  43.3  +  0.1  52 
+M/K-2  92.2  +  2.5  0 
determinant which is present on all CD44 + cells,  including 
those which do not bind HA (data not  shown). 
When  the  IRAWB  14  antibody  was  added  to 
AKR1.CD44 +  ACY cells just  before incubation with  F1- 
HA, either at room temperature or at 4~  binding of F1- 
HA increased from background levels to 40-50 times bach 
ground (Fig. 1, K). Thus, the IRAWB 14 antibody rapidly 
converted CD44 molecules with a deletion of the cytoplasmic 
domain into a form able to bind HA. Antibody was present 
during the  15-20-min incubation  allowed for the binding 
of F1-HA, so the activation occurred within this period. The 
new binding activity was specific, since it was blocked with 
Table  3.  Hyaluronate Dependence of CD4#-mediated  Adhesion 
to  TME-3H3  Cells* 
Cell line  +/-  antibody 
%  of Input cpm 
adhering* 
Untreated  Hyaluronidase- 
TME-3H3  treated TME-3H3 
ceils  cellsS 
AKR1.CD44 § w.t.,  alone  82.5  +  2.0 
AKR1.CD44 + w.t.+KM201  29.7  _+  1.5 
AKR1.CD44 + ACY, alone  27.6  _+  2.4 
AKR1.CD44 + ACY + KM201  20.5  _+  1.5 
22.7  _+  1.7 
19.9  _+  1.9 
22.0  _+  2.2 
ND 
* 3H3 endothelial cells (reference 39) were plated at 2  x  104 cells/well 
in 24-well tissue culture plates the day before the assay was performed. 
Wells were rinsed once with DMEM containing 5% newborn calf se- 
rum before assay. 
* Antibody was a 1:20 dilution of hybridoma supernatant added to the 
slCr-labeled lymphoma cells  just before their addition to culture walls. 
S Mean and standard error of triplicate samples. See legend for Table 1. 
* See figure legend for Table 2. 
* Mean and standard error of triplicate samples. See legend for Table 1. 
S 3H3  cells plated the  day before assay were rinsed twice in warm 
DMEM without serum. Hyalurnnldase (1 mg/ml in DMEM) was added 
to each well (0.5 ml) and the plate incubated at 37~  for 30 min. After 
incubation, the hyaluronidasr was removed and the wells were rinsed 
twice with DMEM containing 5% newborn calf serum at 37~ 
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Figure 3.  Enhancement  of FI-HA binding by CD44-specific  mAb IRAWB 14. The T cell lymphoma BW5147 (A-F) and CD44  h variant of SAKRTLS 
12 (29) (G-L) were stained with fluorescein-conjugated  IM7 (A and G) or with fluorescein-conjugated  hyaluronic acid (FI-HA) (B-F and H-L). Blocking 
or enhancement of F1-HA binding was as described in Fig. 1. The dotted-line insert in each panel is the fluorescence  profile of unstained cells. 
unlabeled HA (Fig.  1, L). Slight (two- to threefold) increases 
in binding of F1-HA to the wild type transfectant were also 
seen  (Fig.  1, E). 
The ability of IRAWB 14 antibody to induce HA binding 
in normal hematopoietic cells was tested on splenic T  cells 
from AKK/Cum mice (Fig. 4). About 45% of the cells were 
CD44 + on the basis of binding of fluoresceinated-IM7 an- 
tibody (first panel, Fig. 4), but binding of F1-HA was nega- 
tive (second~nel, Fig. 4). The few scattered events above back- 
ground in this panel were not competed by unlabeled HA 
(not  shown)  and  so were not  specific.  In  the presence of 
IKAWB 14 antibody, F1-HA binding was induced in 41% 
of the cells (third panel,  Fig.  4), equivalent  to the number 
of CD44 + cells. The binding of F1-HA induced by IRAWB 
14 antibody was competed by unlabeled HA (fourth panel, 
Fig.  4). 
When  total bone marrow was incubated with  IKAWB 
14 and stained for F1-HA binding, most cells were negative, 
though  most  were  strongly  CD44 +  (data  not  shown). 
Thus,  not all CD44 § cells can be induced to bind HA by 
this  antibody. 
Discussion 
AKR1 cells,  transfected with  a CD44 cDNA construct 
coding for a wild-type CD44 molecule, express hyaluronate 
binding activity both for HA in solution and HA immobi- 
lized on plastic culture wells. This result indicates  that CD44 
is able to confer HA binding activity, and if any additional 
factors are needed for HA binding, they are provided by the 
AKR1 cell. Thus, in agreement with Aruffo et al. (24) and 
our previous data (22, 23), the hematopoietic form of CD44 
is a cell surface receptor for HA. Our experiments show that 
the cytoplasmic domain contributes to this function and that 
HA recognition can be dramatically influenced by mAb to 
particular  epitopes. 
Increased binding to a lymph node-derived endothelial cell 
line,  TME-3H3 (37), was shown by the AKR1.CD44 + w.t. 
transfectant, compared with the AKR1 parental cells (Table 
2).  This  increased  binding  was  attributable  to  CD44- 
hyaluronate interactions,  since it could be inhibited by the 
antibody KM201 specific for the hyaluronate binding site on 
CD44 (11, 23),  and by hyaluronidase treatment  of the en- 
dothelial cells (Table 3). This result indicates that CD44 can 
contribute to lymphocyte adhesion to certain endothelial cells 
via its hyaluronate binding activity, in agreement with the 
result of Stamenkovic et al. (25) using cells transfected with 
the hematopoietic form of human CD44.  The results also 
reemphasize that adhesion to endothelial cells may be medi- 
ated by more than one mechanism (48-50), since the CD44- 
negative parental line did adhere to the endothelial  cells, though 
less well than did the transfected cells, and since CD44-specific 
antibody and/or hyaluronidase  only partially inhibited binding 
of the transfectants. Elsewhere, we show that recognition be- 
tween other lymphocyte-endothelial cell line combinations 
is predominantly mediated by VLA-4 and VCAM-1 (37, 41). 
The AKR1 transfectant expressing a CD44 molecule with 
a truncated cytoplasmic domain,  AKR.1CD44 + ACY, did 
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Figure 4.  Induction  of F1-HA binding  by splenic T cells. T cell-enriched spleen cells from AKR/Cum mice were stained with fluorescein-conjugated 
IM7 (tint Panel) or with fluorescein-conjugated hyaluronic acid (F1-HA) (second-fourth panels).  F1-HA-labeled cells were pretreated with IRAWB 14 
mAb (third and fourth panels) and with unlabeled hyaluronic acid (HA) (fourth panel only). The dotted-line insert in each panel is the fluorescence profile 
of unstained cells. 
not bind F1-HA from solution,  but could be induced to do 
so very efficiently by pretreatment with the CD44-specific 
antibody, IRAWB 14. This observation suggests that the mu- 
tant CD44 molecule must be activated in some way in order 
to bind HA. Activation,  as used here, refers to the conver- 
sion of preexisting CD44 molecules from a non-HA-binding 
state to a form able to bind HA. We suggest two possible, 
not necessarily exclusive, mechanisms of antibody-induced 
activation: a conformational change in the CD44 molecule; 
or a change in distribution of the CD44 molecules on the 
cell surface. A change in distribution might involve clustering 
of CD44 molecules into a specific configuration or associa- 
tion of CD44 with other cell surface molecules. Either mech- 
anism may, or may not, require intracellular signalling. The 
cytoplasmic domain of the wild-type molecule could mediate 
either a conformational or distributional  change,  perhaps 
through interaction with cytoplasmic elements. On the other 
hand, antibody-induced activation may mediate HA binding 
by a different mechanism than that mediated by the cyto- 
plasmic domain of the wild-type CD44 molecule. 
AKK1.CD44 § AiCY cells had some affinity for immobi- 
lized HA without antibody activation,  although less than 
cells transfected with the wild-type CD44 molecule. Immobi- 
lized HA, unlike the soluble form, may itself  provide an acti- 
vation stimulus (similar to that provided by the IRAWB 14 
antibody) to effect either a conformational or distributional 
change in the tailless receptors. Alternatively, immobilized 
HA may represent a ligand that can be recognized without 
activation.  The relative inefficiency of binding to immobi- 
lized HA by the CD44 + ACY cell line lacking  the cyto- 
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plasmic domain of CD44 may suggest a requirement for cy- 
toplasmic interactions  to stabilize adhesion. 
The IRAWB 14 antibody activates HA binding on several 
CD44 expressing T cell lymphomas that do not constitu- 
tively bind HA from solution  (e.g., Fig. 3). In these lines, 
failure to bind HA is not due to the absence of a cytoplasmic 
domain: SDS-gel electrophoresis of immunoprecipitates  and 
northern blot analysis indicates no difference in the migra- 
tion of CD44 proteins or spectrum of CD44 mRNAs in these 
lines compared to related lines which bind HA (29). The ability 
of these  CD44 §  HA-receptor negative  cells to bind HA 
upon brief exposure to IRAWB 14 antibody (at 4~  estab- 
lishes that the CD44 on their cell surface  is capable of  forming 
HA receptors  without metabolic alteration. Like the cells trans- 
fected with a CD44 construct containing a mutation affecting 
the cytoplasmic domain, the CD44  hi variant of SAKRTLS 
12,  shown in Fig. 3,  is able to bind to immobilized  HA 
without antibody activation (unpublished results) but requires 
activation to bind HA from solution. Thus, the same mech- 
anisms for antibody or immobilized ligand-mediated recog- 
nition as have been suggested above might be postulated for 
these cells. However, the failure to constitutively bind HA 
must have a different basis than the absence of an intracel- 
lular domain. 
A portion of splenic T cells express CD44 but fail to bind 
HA. As in the case  of the lymphomas discussed  above, IRAWB 
14 antibody induced binding of F1-HA in these normal lym- 
phocytes (Fig. 4).  Other normal hematopoietic cells, such 
as bone marrow myeloid cells, were not induced by IRAWB 
14 to bind F1-HA. Further studies will be required to deter- mine the susceptibility of different hematopoietic cell popu- 
lations to induction of HA binding and the physiological 
factors involved in such induction. 
The failure of many CD44 + calls to bind HA,  and the 
ability of a CD44-specific antibody to activate HA binding, 
suggests that CD44 is a member of the growing list of cell 
adhesion molecules that require activation to bind ligand most 
efficiently (51-56). This list includes many of the integrins: 
platdet GP lib-Ilia (Oqtb/~3) (52);  LFA-1 (51); Mac-1/CK3 
(53-54);/3t-class integrins on developing neurons (55);  and 
Lam-1 (56),  a member of the Lec-Cam (lectin-like) family. 
Best studied to date is the platelet integrin GP lib-Ilia, which 
shows many parallels with the HA-binding requirements of 
the CD44-expressing cells described here. Cells expressing 
this integrin constitutively bind immobilized fibrinogen, but 
require activation,  by antibody or phorbol  ester,  to bind 
fibrinogen from solution.  In this case, antibody activation 
is believed to be due to a conformational change, since anti- 
body can activate detergent-solubilized integrin and monova- 
lent Fab  fragments of antibody can activate (52).  Further, 
there is evidence that ligand can induce an activating confor- 
mational change (57). For several  integrins (GP IIb-IIIa, Mac-l, 
LFA-1, and p150,  95) activation exposes new epitopes that 
are recognized by activation-specific antibodies (52,  54, 58, 
59). On the other hand, localized redistribution of the CR3 
integrin, postulated to result in high affinity adhesion patches, 
has been demonstrated on neutrophils  stimulated to bind 
C3bi by phorbol ester (60).  Alteration or total deletion of 
the cytoplasmic tails of cadherins, integrins, and other cell 
interaction molecules has been shown to dramatically reduce 
ligand binding ability (61-64). 
Most hematopoietic cells in the mouse express CD44 at 
some level (7), yet HA binding is not detectable (22, 23, 28), 
or is only stimulated under particular conditions (28, 65, and 
this paper).  Does this  general failure to  demonstrate HA 
binding by normal hematopoietic cells indicate that CD44 
has functions other than or in addition to HA binding in 
vivo and/or that HA binding is only rarely or transiently 
activated? It is reasonable to suggest that a cell-adhesion mech- 
anism involving such abundant and broadly distributed mol- 
ecules as HA and CD44 could not be constitutively active 
if it is to provide any selectivity of interaction, and that specific 
activation signals would be required to elicit function at the 
appropriate times and locations. The intracellular mechanisms 
by which different cell types regulate CD44 activity and the 
physiological factors involved in triggering activation to allow 
binding of HA remain to be defined. 
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